Status:
COMPLETED
A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions
Lead Sponsor:
Bayer
Conditions:
Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study, in which data from Taiwanese people with indolent non-Hodgkin lymphoma who will be receiving copanlisib is studied. Indolent non-Hodgkin lymphoma (iNHL) is a type of c...
Eligibility Criteria
Inclusion
- Patients with confirmed diagnosis of r/r iNHL
- Patients ages ≥ 18 years old when first dosed with copanlisib for iNHL.
- Patients who will receive copanlisib or received at least one dose of copanlisib after 01-Nov-2019
- Patients or his/her legal guardian or representative agree to provide the written informed consent or a waiver of informed consent granted by local IRB
Exclusion
- Patients who had participated in the global clinical study for copanlisib before local market approval
- Patients who participate in an interventional trial during the data collection period
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2024
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT05217914
Start Date
July 1 2022
End Date
August 31 2024
Last Update
October 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations
Multiple Locations, Taiwan